Treatment-induced NE differentiation in cancer cells is proposed to adopt the molecular program of normal neuronal development, based on the observation that the AD-to-NE lineage transition in prostate cancer (PCa) can be evoked by several key neural differentiation transcription factors (TFs) such as ASCL1 (17), ONECUT2 (18), NEUROD1 (19), N-MYC (20, 21), and BRN2 (22). Here, ASCL1 is linked to posterior cortical atrophy.